Paris’s Klineo Clinches €2mn for Its Trailblazing AI Platform in the Battle Against Cancer
Have you heard the news? From the heart of Paris, a groundbreaking step has been taken by Klineo. This innovative startup just secured a whopping €2 million to supercharge its AI platform, designed to be a beacon of hope for those navigating the tough journey of cancer clinical trials. Intriguing, right? Let’s dive deeper!
Connecting Dots: Doctors, Patients, and Clinical Trials
Klineo isn’t just any platform; it’s a lifeline connecting doctors and patients directly to the clinical trials that matter most. Imagine being able to search for trials, get in touch with medical centers, and receive real-time updates and notifications whenever a trial that matches a patient’s criteria pops up. Yes, Klineo makes this a reality. It’s like having a personal assistant for battling cancer, focusing specifically on skin cancer, breast cancer, and lymphoma cases for now.
The Brains Behind the Operation
In 2021, an oncologist named Dr. Arnaud Bayle, alongside two tech wizards, Thomas Peyresblanques and Nicolas Drizard, decided it was time to change the game. They founded Klineo with a vision to streamline the overwhelming journey for those affected by cancer, seeking new treatments through clinical trials.
A Beacon of Hope
Let’s face it, the road to finding and participating in a clinical trial can feel like searching for a needle in a haystack. But here’s where Klineo shines, aiming to speed up the process of patient inclusion in clinical trials. Dr. Bayle put it simply yet powerfully, “Today, too few patients benefit from a clinical trial because the search for one is a very tedious process.” This reality is something Klineo is determined to change.
A Closer Look at the Numbers
Did you know that less than 10% of cancer patients who could participate in clinical trials actually do so? And to add to the challenge, about 20% of clinical trials don’t see the light of day due to not enough participants. Dr. Bayle and his team are on a mission to ensure doctors and patients everywhere can easily access new, personalized therapeutic options, pushing medical research forward.
What’s Next for Klineo?
With the fresh injection of €2 million, Klineo has ambitious plans. The startup is setting its sights on covering every type of cancer trial in France by the end of 2024, kicking things off with lung cancer. Additionally, there’s talk of expanding the team and giving the platform itself a boost to better serve its users. And let’s not forget, this round of funding was Klineo’s first leap into fundraising, attracting support from the French public investment bank BPI and a handful of business angels.
But Klineo’s vision doesn’t stop at the borders of France. Looking ahead, the startup is keen on bringing its services to international waters, aiming to include trials for not just cancer but also rare and neurological diseases. Now, that’s a future worth watching!
So, what do you think? Is Klineo the key to unlocking a new era in clinical trials and cancer treatment? The journey is just beginning, and it’s certainly an exciting one to follow!
